These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33568689)

  • 1. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.
    Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
    Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
    J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
    Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
    J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
    Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ
    J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-derived neurotrophic factor in patients with Huntington's disease.
    Zuccato C; Marullo M; Vitali B; Tarditi A; Mariotti C; Valenza M; Lahiri N; Wild EJ; Sassone J; Ciammola A; Bachoud-Lèvi AC; Tabrizi SJ; Di Donato S; Cattaneo E
    PLoS One; 2011; 6(8):e22966. PubMed ID: 21857974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.
    Ciammola A; Sassone J; Cannella M; Calza S; Poletti B; Frati L; Squitieri F; Silani V
    Am J Med Genet B Neuropsychiatr Genet; 2007 Jun; 144B(4):574-7. PubMed ID: 17427191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
    Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A
    J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients.
    Gutierrez A; Corey-Bloom J; Thomas EA; Desplats P
    Front Mol Neurosci; 2019; 12():335. PubMed ID: 32038165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ
    Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms.
    Betti L; Palego L; Unti E; Mazzucchi S; Kiferle L; Palermo G; Bonuccelli U; Giannaccini G; Ceravolo R
    Arch Ital Biol; 2018 Jul; 156(1-2):27-39. PubMed ID: 30039833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
    van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
    Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
    J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Downregulation of p75
    Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
    Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
    Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
    PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.
    Smail S; Bahga D; McDole B; Guthrie K
    Chem Senses; 2016 Mar; 41(3):221-32. PubMed ID: 26783111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.